Development of Mult-Spectral Fluorescence Scanning Fiber Endoscope (SFE)

$263,206U54FY2011CANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 39018356 Paper 39007490 Paper 38781019 Paper 38763697 Paper 38453895 Paper 38329812 Paper 38275234 Paper 38169937 Paper 36327434 Paper 36140433 Paper 35299273 Paper 35267943 Paper 34758158 Paper 34416429 Paper 33293425 Paper 33290281 Paper 33130332 Paper 33028666 Paper 32519141 Paper 32251017 Paper 32025000 Paper 31715145 Paper 31093519 Paper 30578782 Paper 30334022 Paper 30224903 Paper 29870260 Paper 29608884 Paper 29432922 Paper 29307847 Paper 29152066 Paper 28899060 Paper 28560244 Paper 28555172 Paper 27766208 Paper 27363029 Paper 27239250 Paper 26709709 Paper 26426999 Paper 26317790 Paper 26192918 Paper 26181290 Paper 26068949 Paper 25975605 Paper 25743456 Paper 25157622 Paper 25027002 Paper 24828664 Paper 24768332 Paper 24562382 Paper 24120334 Paper 23966226 Paper 23872488 Paper 23857478 Paper 23684943 Paper 23658246 Paper 23605564 Paper 23525077 Paper 23524127 Paper 23502247 Paper 23403908 Paper 23041325 Paper 23022051 Paper 22563192 Paper 22100819 Paper 21751414 Paper 21576902 Paper 21530871 Paper 20637198

Abstract

Project Summary: A multi-spectral scanning fiber endoscope (SFE) will be developed to image the panel of fluorescent-labeled pepfides developed in Project 2 that have specific binding activity to amplified and/or over expressed gene targets identifled in Project 1. Image processing algorithms will be developed to stitch together individual images to form a panorama of the esophageal mucosal surface, and "red-flag" idenfificafion of highgrade dysplasia and early adenocarcinoma will be performed in Core B to assist the physician by guiding biopsy. The performance of this integrated imaging strategy will be validated in Core C. This instrument will pass through the working channel of a medical endoscope in Phase 1 clinical studies of the individual pepfides assigned to three fiuorescent-labels in Project 2. The expected establishment of safety will prepare this system for a future multi-center clinical validation study.

View original record on NIH RePORTER →